Impact of Brokerage Rating on Incyte Corporation(INCY)

Many Incyte Corporation(INCY) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Incyte Corporation was Initiated by Credit Suisse to Outperform on Jan 23, 2017.

Company has reported several Insider transactions to the SEC, on Jan 11, 2017, Reid M Huber (EVP, Chief Scientific Officer) sold 11,739 shares at 113.55 per share price.On Nov 17, 2016, Paula J Swain (EVP, Human Resources) sold 10,000 shares at 103.26 per share price.On Oct 11, 2016, Barry P Flannelly (EVP & General Manager US) sold 24,204 shares at 97.00 per share price.

Incyte Corporation Last issued its quarterly earnings results on Feb 14, 2017. The company reported $0.05 EPS for the quarter, missing the analyst consensus estimate by $ -0.18. Analyst had a consensus of $0.23. The company had revenue of $326.50 million for the quarter, compared to analysts expectations of $327.14 million. The companys revenue was up 33.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.29 EPS.

Incyte Corporation (NASDAQ:INCY) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1.19 by 13 Brokerage Firm. 10 Wall Street Firms have rated the stock as a strong buys. 3 stock experts have also suggested a buy rating.

Incyte Corporation (NASDAQ:INCY): The mean estimate for the short term price target for Incyte Corporation (NASDAQ:INCY) stands at $118.17 according to 12 Analysts. The higher price target estimate for the stock has been calculated at $140 while the lower price target estimate is at $92.

Incyte Corporation (NASDAQ:INCY) rose 1.79% or 2.17 points on Tuesday and made its way into the gainers of the day. After trading began at $119.94 the stock was seen hitting $125.49 as a peak level and $119.6201 as the lowest level. The stock ended up at $123.32. The daily volume was measured at 1,869,498 shares. The 52-week high of the share price is $125.49 and the 52-week low is $60.3. The company has a market cap of $23,232 million.

Incyte Corp is a drug discovery company that is using its expertise in genomics, medicinal chemistry and molecular, cellular and in vivo biology to discover and develop novel therapeutics. The company has three fully-staffed drug discovery programs underway focused primarily on the identification of new small molecule drugs for cancer and inflammation. Incyte also has strategic alliances with Lexicon Genetics and Medarex focused on the discovery and development of protein therapeutics or antibodies to treat inflammatory diseases and cancer.

Incyte

For any feedback and suggestions contact author at Nancy.Wright@thefoundersdaily.com

Add Comment